Should You Buy Compass Therapeutics Inc. (CMPX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
CMPX is not a good buy right now for a Beginner long-term investor with $50k–$100k who is impatient. Despite a constructive technical setup and bullish options skew, this is still a pre-revenue biotech with catalyst-driven outcomes and no proprietary buy signals today. A better stance is HOLD/WAIT for the upcoming end-of-Q1 clinical update (or for a clearer technical breakout above resistance) before committing meaningful capital.
Technical Analysis
Trend is moderately bullish but not at a clear low-risk entry today. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating an established uptrend. RSI(6) ~57 is neutral (not oversold), so it’s not screaming “dip buy.” MACD histogram is positive (0.0584) but contracting, suggesting upside momentum is still present but weakening. Price 6.145 is just above the pivot (5.972); nearby support is 5.571 (S1) and resistance is 6.373 (R1) then 6.621 (R2). After today’s -4.06% drop, the stock is still in an uptrend structure, but risk-reward is better either closer to support (near ~5.57) or on a decisive breakout/close above ~6.37–6.62.
Analyst Ratings and Price Target Trends
Recent trend: improving/constructive. Canaccord initiated with Buy and a $10 price target (2025-12-03). William Blair initiated with Outperform and no explicit price target (2026-01-05), citing potential success for tovecimig and upcoming end-of-Q1 disclosures that could support regulatory filings.
Wall Street pros view: upside tied to clinical data readouts and potential regulatory path; improving visibility via new coverage.
Wall Street cons view: the thesis is highly dependent on trial outcomes/timelines; lack of current revenue means valuation support is mostly narrative/catalyst-based.
Influential/politician trading: No recent congress trading data available; no notable politician activity indicated. Hedge funds/insiders: neutral trends.
Wall Street analysts forecast CMPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPX is 12.67 USD with a low forecast of 8 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast CMPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPX is 12.67 USD with a low forecast of 8 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 6.160
Current: 6.160
